Venture capital firm
Invus portfolio
invus.comInvus is a venture capital firm based in New York, United States, founded in 1985. It has invested in 83 venture-backed companies across 110 funding rounds on VCMC, and led 14 of those rounds. 14 of them were in the last 12 months.
83
Venture-backed companies
in its portfolio on VCMC
110
Funding rounds
led 14
14
Last 12 months
rounds, Oct 2025 to Sep 2026
21
With a disclosed valuation
of 83 companies
$94.3B
Combined value of its private companies
the whole companies, not what Invus owns
82 private companies Invus has backed have a VCMC valuation; together they are worth $94.3B. That is the value of the whole companies, not what Invus owns. Bolt is 9% of the total. 1 company it backed has since been acquired and is not included. How VCMC values companies.
Values cover private companies only; public companies are not included.
Portfolio
Invus' most valuable portfolio companies
The 10 most valuable private companies Invus has backed, by VCMC's valuation. Values cover private companies only; public companies are not included.
- 1 Bolt Payment Processing & Point of Sale, San Francisco $8.4B range $706M – $13.9B Joined at Series E, 2022
- 2 Vinted Salvage Merchandise & Thrift Stores, Wilmington $6.7B range $4.8B – $7.7B Joined at Growth, 2024
- 3 Kailera Therapeutics Pharmaceutical Products, Waltham $5.5B range $2.6B – $7.8B Joined at Series B, 2025
- 4 Pharmaceutical Products, Shanghai $3.9B range $2.1B – $6.3B Joined at Series D, 2026
- 5 Encoded Therapeutics Biotechnology, South San Francisco $3.6B range $2.3B – $6.8B Joined at Series F, 2026
- 6 eGenesis Biotechnology, Cambridge $3.3B range $1.3B – $5.1B Joined at Series C, 2021
- 7 Rapido Taxicabs, Hyderabad $3.1B range $2.6B – $3.8B Joined at Series E, 2024
- 8 Oxford Quantum Circuits Tech Companies, Reading $3.0B range $1.9B – $5.0B Joined at Series C, 2026
- 9 Mirador Biotechnology, San Diego $2.8B range $1.2B – $4.3B Joined at Series A, 2024
- 10 Pharmaceutical Products, Burlington $2.6B range $622M – $4.5B Joined at Series B, 2024
Portfolio
Full Invus portfolio (83 companies)
83 companies. Load more shows the rest.
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Vinted Salvage Merchandise & Thrift Stores · since Growth, 2024 | Other Apr 2026 $1.03B | $6.7B | $4.8B – $7.7B | $6.7B (0%) | $601M | 0% | 4,599 | growing | A | |
| 2 | ElevateBio Pharmaceutical Products · since Series B, 2020 | Series D May 2023 $401M | $2.4B | $693M – $9.9B | $1.7B (-30%) | $720M | 79% | 450 | down | D | |
| 3 | Cerevel Pharmaceutical Products · since Growth, 2020 | Debt Aug 2022 $300M | $755M | $100M – $2.4B | $679M (-10%) | $151M | 46% | 140 | unknown | D | |
| 4 | Kailera Therapeutics Pharmaceutical Products · since Series B, 2025 | Series B Oct 2025 $600M | $5.5B | $2.6B – $7.8B | $5.5B (0%) | $608M | 0% | 26 | unknown | B | |
| 5 | Bolt Payment Processing & Point of Sale · since Series E, 2022 | Bridge Sep 2026 $27M | $8.4B | $706M – $13.9B | $7.8B (-8%) | $1.6B | 2% | 796 | flat | D | |
| 6 | Mirador Biotechnology · since Series A, 2024 | Series B Sep 2025 $250M | $2.8B | $1.2B – $4.3B | $2.8B (0%) | $307M | 0% | 97 | up | C | |
| 7 | LifeMine Biotechnology · since Series C, 2022 | Series E Aug 2026 $263M | $2.0B | $1.4B – $2.9B | $1.9B (-8%) | $288M | 97% | 32 | shrinking | B | |
| 8 | Xendit Payment Processing & Point of Sale · since Series D, 2022 | Debt Sep 2024 $50M | $1.4B | $170M – $3.8B | $1.3B (-10%) | $377M | 28% | 620 | flat | D | |
| 9 | Encoded Therapeutics Biotechnology · since Series F, 2026 | Series F Sep 2026 $275M | $3.6B | $2.3B – $6.8B | $4.5B (+26%) | $492M | 0% | 192 | up | B | |
| 10 | Oxford Quantum Circuits Tech Companies · since Series C, 2026 | Series C Jun 2026 $350M | $3.0B | $1.9B – $5.0B | $3.5B (+18%) | $419M | 0% | 159 | up | B | |
| 11 | eGenesis Biotechnology · since Series C, 2021 | Series D Sep 2024 $191M | $3.3B | $1.3B – $5.1B | $2.3B (-30%) | $368M | 0% | 154 | up | C | |
| 12 | Rapido Taxicabs · since Series E, 2024 | Growth Equity May 2026 $240M | $3.1B | $2.6B – $3.8B | $3.3B (+6%) | $346M | 0% | 5,861 | growing | A | |
| 13 | Rain Tech Companies · since Series B, 2025 | Series B Apr 2025 $75M | $539M | $294M – $620M | $539M (0%) | $59.3M | 0% | 363 | up | B | |
| 14 | Universal Quantum Electronical Components Manufacturing · since Series A, 2026 | Series A Oct 2026 $100M | $523M | $335M – $1.4B | $917M (+75%) | $140M | 0% | 103 | up | C | |
| 15 | Tech Companies · since Series A, 2022 | Series B Jun 2024 $70M | $454M | $153M – $951M | $240M (-47%) | $79.9M | 59% | 177 | down | C | |
| 16 | Tech Companies · led at Series C, 2023 | Series C Oct 2023 $31M | $151M | $48.7M – $540M | $105M (-30%) | $39.1M | 80% | 59 | down | D | |
| 17 | Tech Companies · led at Series A, 2025 | Series A Jun 2025 $14M | $131M | $45.9M – $200M | $131M (0%) | $20.0M | 0% | 78 | up | C | |
| 18 | Pharmaceutical Products · since Series C, 2021 | Series D Nov 2025 $115M | $1.6B | $884M – $2.4B | $1.5B (-7%) | $210M | 34% | 127 | up | B | |
| 19 | Loans & Financing · since Series C, 2023 | Debt Dec 2025 $140M | $2.0B | $883M – $3.3B | $2.0B (0%) | $241M | 0% | 2,090 | growing | C | |
| 20 | Financial Services · since Series A, 2019 | Growth Equity Oct 2021 $150M | $1.5B | $189M – $2.7B | $1.5B (0%) | $176M | 10% | 485 | up | D | |
| 21 | Biotechnology · since Series B, 2026 | Series B Oct 2026 $135M | $976M | $634M – $2.2B | $1.4B (+48%) | $159M | 0% | 95 | growing | C | |
| 22 | Cryptocurrency · since Series C, 2021 | Series C May 2021 $250M | $1.9B | $277M – $3.0B | $1.9B (-3%) | $384M | 0% | 876 | up | D | |
| 23 | Pharmaceutical Products · since Series B, 2024 | Series B Jul 2024 $260M | $2.6B | $622M – $4.5B | $1.4B (-44%) | $335M | 22% | 75 | flat | C | |
| 24 | Medical Supply Manufacturers · since Series D, 2026 | Series D Sep 2026 $250M | $1.0B | $869M – $1.5B | $1.3B (+28%) | $144M | 0% | 148 | growing | A | |
| 25 | Biotechnology · since Series C, 2024 | Series C Apr 2024 $133M | $1.8B | $698M – $2.6B | $1.2B (-36%) | $198M | 0% | 53 | up | C | |
| 26 | Biotechnology · since Series A, 2021 | Series C Jun 2026 $85M | $744M | $487M – $1.1B | $653M (-12%) | $106M | 97% | 53 | shrinking | B | |
| 27 | Pharmaceutical Products · since Series D, 2026 | Series D Jan 2026 $287M | $3.9B | $2.1B – $6.3B | $4.2B (+7%) | $526M | 0% | 64 | growing | B | |
| 28 | Biotechnology · since Series A, 2023 | Series C Jun 2026 $65M | $649M | $390M – $1.2B | $771M (+19%) | $84.8M | 0% | 58 | growing | B | |
| 29 | Biotechnology · since Series A, 2023 | Series A Apr 2023 $270M | $380M | $196M – $997M | $228M (-40%) | $337M | 97% | 13 | shrinking | C | |
| 30 | Biotechnology · since Series C, 2021 | Series C May 2021 $200M | $470M | $75.1M – $2.5B | $421M (-10%) | $213M | 54% | 37 | flat | D | |
| 31 | Biotechnology · since Series B, 2026 | Grant Sep 2026 $8.0M | $1.1B | $660M – $2.0B | $1.4B (+25%) | $155M | 0% | 50 | growing | B | |
| 32 | Financial Services · led at Growth, 2021 | Debt Feb 2025 $38M | $664M | $107M – $952M | $653M (-2%) | $89.7M | 8% | 481 | up | D | |
| 33 | Biotechnology · since Series B, 2022 | Series B May 2022 $150M | $134M | $72.6M – $392M | $111M (-17%) | $156M | 97% | 42 | shrinking | C | |
| 34 | Biotechnology · since Series B, 2025 | Series B Dec 2025 $120M | $1.3B | $582M – $2.0B | $1.3B (+5%) | $146M | 0% | 65 | up | C | |
| 35 | Groceries · led at Series C, 2021 | Series D Jun 2025 $120M | $1.3B | $840M – $1.5B | $1.3B (0%) | $168M | 0% | 1,451 | up | B | |
| 36 | Pharmaceutical Products · since Series B, 2022 | Growth Equity Dec 2025 $35M | $362M | $227M – $552M | $310M (-14%) | $37.3M | 49% | 80 | down | B | |
| 37 | Biotechnology · since Series B, 2026 | Series B Oct 2026 $150M | $1.1B | $704M – $2.4B | $1.6B (+47%) | $177M | 0% | 31 | flat | C | |
| 38 | Biotechnology · since Series A, 2021 | Series C Apr 2024 $55M | $176M | $119M – $357M | $103M (-41%) | $48.9M | 97% | 14 | shrinking | B | |
| 39 | Pharmaceutical Products · since Series B, 2019 | Series E Dec 2023 $101M | $148M | $72.3M – $368M | $80.8M (-46%) | $35.9M | 97% | 25 | down | C | |
| 40 | Gas Stations · led at Series C, 2019 | Series D May 2022 $125M | $2.0B | $277M – $2.8B | $1.9B (-6%) | $237M | 0% | 294 | up | D | |
| 41 | Pharmaceutical Products · since Series B, 2020 | Series C Jul 2024 $100M | $1.1B | $293M – $1.6B | $742M (-35%) | $126M | 0% | 34 | flat | C | |
| 42 | Pharmaceutical Products · since Series A, 2020 | Series B Dec 2024 $147M | $1.5B | $414M – $2.3B | $1.5B (0%) | $178M | 0% | 35 | flat | C | |
| 43 | Biotechnology · since Series B, 2021 | Series C Mar 2023 $87M | $151M | $71.7M – $576M | $91.9M (-39%) | $88.2M | 97% | 43 | shrinking | D | |
| 44 | Biotechnology · since Series B, 2022 | Series B Aug 2022 $200M | $1.7B | $445M – $4.1B | $1.7B (-1%) | $307M | 5% | 70 | growing | D | |
| 45 | Biotechnology · since Series B, 2021 | Series C Jun 2024 $90M | $369M | $194M – $937M | $175M (-53%) | $105M | 97% | 32 | shrinking | C | |
| 46 | Employment Agencies & HR Consulting · since Growth, 2016 | Debt Jan 2022 $65M | $315M | $52.2M – $1.2B | $315M (0%) | $110M | 49% | 112 | down | D | |
| 47 | Biotechnology · since Series B, 2024 | Series B Apr 2024 $132M | $1.2B | $280M – $2.1B | $652M (-44%) | $167M | 31% | 43 | flat | D | |
| 48 | Biotechnology · since Series B, 2025 | Series B Dec 2025 $110M | $1.3B | $636M – $1.9B | $1.4B (+6%) | $149M | 0% | 35 | growing | B | |
| 49 | Biotechnology · since Series B, 2021 | Series B Apr 2021 $189M | $780M | $65.0M – $2.2B | $719M (-8%) | $219M | 21% | 84 | flat | D | |
| 50 | Biotechnology · since Series C, 2022 | Acquisition Oct 2025 $410M | $902M acquired 2025 | $123M – $1.3B | – | – | 0% | 52 | flat | D |
Valuation: VCMC's valuation with its range, from a low to a high scenario; a company with no valuation shows a dash, one acquired after its last round its last value as a private company.
Activity
How Invus invests: stages, industries and countries
Most of its rounds are Series C and later (48%). Its companies span 21 industries, most in Biotechnology, Tech Companies and Pharmaceutical Products, across 11 countries.
Rounds by stage
- Series A 25
- Series B 32
- Series C and later 53
Investments by industry
- Biotechnology 33
- Tech Companies 13
- Pharmaceutical Products 12
- Medical Supply Manufacturers 5
- Financial Services 2
- Groceries 2
- Payment Processing & Point of Sale 2
- Beverages & Refreshments 1
Investments by country
- United States 61
- United Kingdom 6
- France 4
- India 4
- Switzerland 2
- Brazil 1
Recent rounds
Invus' latest investments
Invus' most recent funding rounds, newest first. 14 rounds in the last 12 months.
- Series B $135M 13 Oct 2026
- Universal Quantum Series A $100M 8 Oct 2026
- Series B $150M 7 Oct 2026
- Series D $52M 5 Oct 2026
- Series D $250M 24 Sep 2026
- Encoded Therapeutics Series F $275M 9 Sep 2026
- Series A $18M 27 Aug 2026
- LifeMine Series E $263M 7 Aug 2026
- Series C $85M 30 Jun 2026
- Oxford Quantum Circuits Series C $350M 3 Jun 2026
Co-investors
Invus' top co-investors
The investors that most often join the same rounds as Invus. ARCH Venture Partners leads, with 14 rounds together.
- ARCH Venture Partners 14 rounds together
- 12 rounds together
- 11 rounds together
- 9 rounds together
- GV 9 rounds together
- 8 rounds together
- 7 rounds together
- 7 rounds together
- QED Investors 7 rounds together
- 7 rounds together
About
About Invus
The Invus Group, LLC is an American private equity firm that provides investment advisory and management services across private and public equity markets. The company operates globally, with offices in the United States, Europe, and Asia, and focuses on sectors such as fintech, marketplace, healthcare, and software. Invus manages investments in private companies, public companies, and private biotech firms, and also runs a fund-of-funds strategy targeting emerging and early-stage hedge fund managers. The firm is registered with the U.S. Securities and Exchange Commission.
Description from Veridion's company data.
- Founded
- 1985
- Based in
- New York, United States
- Team
- 89 people, +3% in a year
- Type
- Venture capital firm
Focus markets
- Financial Services
- Healthcare
- Technology
- Consumer Goods
What Invus offers
- Private Equity Investment Management
- Public Equity Investment Management
- Fund-of-Funds Management
- Early-Stage Venture Capital Investment
- Private Biotech Investment Management
- Strategic Entrepreneur Partnership Services
- Company Lifecycle Value Addition Services
- Investment Advisory Services
Questions
Invus: frequently asked questions
How many companies has Invus invested in?
83 venture-backed companies on VCMC, across 110 funding rounds.
What are Invus' most valuable private companies?
Bolt ($8.4B), Vinted ($6.7B), Kailera Therapeutics ($5.5B), by VCMC's valuation.
What was Invus' latest investment?
Soufflé Therapeutics, a Series B round in Oct 2026 of $135M.
Which stages does Invus invest in?
Invus invests most often at Series C and later (53 rounds), followed by Series B (32) and Series A (25).
What is Invus' portfolio worth?
Its private companies with a VCMC valuation are worth $94.3B together. That is the sum of the companies' values, not what Invus owns.
Who does Invus invest alongside?
ARCH Venture Partners (14 rounds), Polaris Partners (12 rounds), RA Capital (11 rounds).